ClinicalTrials.gg
Active, not recruitingNCT05277051Updated Oct 19, 2026

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

A Phase 1 interventional study of Remzistotug and Dostarlimab in Neoplasms, sponsored by GlaxoSmithKline. Active, not recruiting at 26 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Updated Oct 19, 2026Primary completion moved1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
152
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a first time in-human (FTIH) study designed to investigate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of remzistotug in participants with select loco-regionally recurrent solid tumors or metastatic solid tumors where curative or standard treatment options have been exhausted.

02

Conditions studied

  • Neoplasms

Keywords

  • Advanced solid tumors
  • Metastatic solid tumor
  • Anticancer agents
  • Dostarlimab
  • Remzistotug
  • GSK4428859A
  • Belrestotug
  • Nelistotug
  • GSK5764227
  • Head and neck squamous cell carcinoma (HNSCC)
  • Non-small-cell lung cancer (NSCLC)
  • Breast cancer (BC)
  • Clear cell renal cell cancer (ccRCC)
  • Gastric cancer (GC)
  • Colorectal cancer (CRC)
  • Endometrial cancer (EC)
  • Epithelial ovarian
  • fallopian tube
  • and primary peritoneal cancers
03

In context

Neoplasms

10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's enrollment of 152 is above the median of 60 across 7,712 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:

    • Is not a woman of (WOCBP) or
    • Is a WOCBP and using a method that is highly effective with a failure rate of less than (\<)1 percent ([%] per year), during the intervention period and for specified time after end of study treatment.
    • A WOCBP must have a negative highly sensitive pregnancy test within 24-48 hours before the first dose of study intervention.
    • Requirement for Arm I only: Male participants agree to use contraception and for their female partner to use contraception, if applicable.
  • Histological or cytological documentation of loco-regionally recurrent solid tumors where curative treatment options have been exhausted, or solid tumors; types as follows:

    • head and neck squamous cell carcinoma (HNSCC)
    • non-small-cell lung cancer (NSCLC)
    • breast cancer (BC)
    • clear cell renal cell cancer (ccRCC)
    • gastric cancer (GC)
    • colorectal cancer (CRC)
    • endometrial cancer (EC)
    • epithelial ovarian, fallopian tube, and primary peritoneal cancers- Disease that has progressed after standard therapy for the specific tumor type, or for which standard therapy has proven to be ineffective, intolerable, or is considered inappropriate, or if no further standard therapy exists.
    • per 1.1.
  • (ECOG) performance status (PS) 0-1.
  • of at least 12 weeks.
  • Adequate organ function, as defined in the protocol.
  • For participants enrolled in a PK/PD cohort, participant agrees to a fresh tumor during Screening and at approximately 6-weeks after treatment initiation.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with the following therapies (specified time periods are from last dose of prior treatment to first dose of study intervention):

    • Any therapy directed against Polio virus receptor (PVR)-related immunoglobulin domain-containing (PVRIG) (COM701 or other anti-PVRIG monoclonal antibody [mAb]) or other cluster of differentiation (CD)226 axis receptor (T-cell immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain [TIGIT] or CD96) at any time.
    • For Arm I only, prior treatment with orlotamab, enoblituzumab, I-Dxd, or other B7-H3 targeted agents.
    • Other prior immunotherapy, chemotherapy, targeted therapy, biological therapy or radiation therapy within specified periods as defined in the protocol.
    • therapy: if the participant has participated in a clinical study and has received an investigational product within 4 weeks or 5 half-lives of the investigational product (whichever is shorter).
  • Prior allogenic or bone marrow transplantation or other solid organ transplantation.
  • Toxicity from previous anticancer treatment, including:

    • Greater than or equal to Grade 3 immune-mediated toxicity considered related to prior immunotherapy and that led to treatment discontinuation; or
    • History of myocarditis of any grade during a previous treatment with immunotherapy
    • Toxicity related to prior treatment that has not resolved to less than or equal to (\<=) Grade 1. Non Grade 2 toxicities, not constituting a safety risk by investigator judgment are allowed.
  • Participant has a known additional that progressed or required active treatment within the last 2 years.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Participants Receiving remzistotug Monotherapy (Arm A)

    Drug: Remzistotug

  • Experimental
    Participants Receiving remzistotug Plus Dostarlimab (Arm B)

    Drug: Remzistotug · Drug: Dostarlimab

  • Experimental
    Participants Receiving remzistotug Plus Dostarlimab Plus belrestotug (Arm C)

    Drug: Remzistotug · Drug: Dostarlimab · Drug: Belrestotug

  • Experimental
    Participants Receiving Dostarlimab Plus belrestotug (Arm D)

    Drug: Dostarlimab · Drug: Belrestotug

  • Experimental
    Participants Receiving dostarlimab Plus belrestotug Plus remzistotug (Arm E)

    Drug: Remzistotug · Drug: Dostarlimab · Drug: Belrestotug

  • Experimental
    Participants Receiving dostarlimab Plus belrestotug Plus nelistotug (Arm F)

    Drug: Dostarlimab · Drug: Belrestotug · Drug: Nelistotug

  • Experimental
    China Cohort: Participants receiving dostarlimab (Arm G)

    Drug: Dostarlimab

  • Experimental
    Participants Receiving GSK5764227 Plus dostarlimab (Arm I)

    Drug: Dostarlimab · Drug: GSK5764227

Interventions

  • DrugRemzistotug

    Remzistotug will be administered.

  • Dostarlimab will be administered.

  • Belrestotug will be administered.

  • Nelistotug will be administered.

  • GSK5764227 will be administered.

06

What researchers measure

Primary outcomes

  1. Arms A, B, C, I: Number of Participants with dose-limiting toxicities (DLTs)

    Time frame: Up to 21 days

  2. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Up to 27 months

Secondary outcomes

  1. Number of Participants With Clinically Significant Changes in Laboratory Parameters, Electrocardiogram (ECG) and Vital Signs

    Time frame: Up to 24 months

  2. Number of Participants With Dose Reductions or Delays

    Time frame: Up to 24 months

  3. Number of Participants With Withdrawals due to AEs

    Number of participants with adverse events leading to permanent discontinuation of study treatment or withdrawal from study by overall frequency will be assessed.

    Time frame: Up to 27 months

  4. Overall Response Rate (ORR)

    Objective response rate will be calculated as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. It is defined as the percentage of participants with a best overall confirmed complete response (CR) or partial response (PR) at any time as per disease-specific criteria.

    Time frame: Up to 24 months

  5. Number of Participants With Positive Antidrug Antibodies (ADA) to remzistotug

    Time frame: Up to 27 months

  6. Titres of ADA to remzistotug

    Time frame: Up to 27 months

  7. Number of Participants With Positive ADA to Dostarlimab

    Time frame: Up to 27 months

  8. Titers of ADA to Dostarlimab

    Time frame: Up to 27 months

  9. Number of Participants With Positive ADA to belrestotug

    Time frame: Up to 27 months

  10. Titers of ADA to belrestotug

    Time frame: Up to 27 months

  11. Number of Participants With Positive ADA to nelistotug

    Time frame: Up to 27 months

  12. Titers of ADA to nelistotug

    Time frame: Up to 27 months

  13. Number of Participants With Positive ADA to GSK5764227

    Time frame: Up to 27 months

  14. Titers of ADA to GSK5764227

    Time frame: Up to 27 months

  15. Serum Concentrations of remzistotug

    Time frame: Up to 4 months

  16. Serum Concentrations of dostarlimab

    Time frame: Up to 4 months

  17. Serum Concentrations of belrestotug

    Time frame: Up to 4 months

  18. Serum Concentrations of nelistotug

    Time frame: Up to 4 months

  19. Serum Concentrations of GSK5764227

    Time frame: Up to 4 months

  20. Maximum Observed Plasma Concentration (Cmax) of remzistotug Monotherapy

    Time frame: Up to 27 months

  21. Cmax of remzistotug in Combination With Dostarlimab

    Time frame: Up to 27 months

  22. Cmax of remzistotug in Combination With dostarlimab and belrestotug

    Time frame: Up to 27 months

  23. Cmax following administration of dostarlimab with belrestotug

    Time frame: Up to 27 months

  24. Minimum Observed Plasma Concentration (Cmin) of remzistotug Monotherapy

    Time frame: Up to 27 months

  25. Cmin of remzistotug in Combination With Dostarlimab

    Time frame: Up to 27 months

  26. Cmin of remzistotug in Combination With dostarlimab and belrestotug

    Time frame: Up to 27 months

  27. Cmin following administration of dostarlimab with belrestotug

    Time frame: Up to 27 months

  28. Area Under the Plasma Concentration Curve From Time Zero to Last Time of Quantifiable Concentration (AUC[0-t]) of remzistotug

    Time frame: Up to 27 months

  29. AUC(0-t) of remzistotug in Combination With Dostarlimab

    Time frame: Up to 27 months

  30. AUC(0-t) of remzistotug in Combination With dostarlimab and belrestotug

    Time frame: Up to 27 months

  31. AUC(0-t) following administration of dostarlimab with belrestotug

    Time frame: Up to 27 months

  32. AUC From Time Zero to Infinity (AUC[0-infinity]) of Single Dosing of remzistotug

    Time frame: Up to 27 months

  33. AUC(0-infinity) of Single Dosing of remzistotug in Combination with Dostarlimab

    Time frame: Up to 27 months

  34. AUC(0-infinity) of Single Dosing of remzistotug in Combination With dostarlimab and belrestotug

    Time frame: Up to 27 months

  35. AUC(0-infinity) of Single Dosing of remzistotug following administration of dostarlimab with belrestotug

    Time frame: Up to 27 months

  36. Cmax of dostarlimab in Combination With remzistotug

    Time frame: Up to 27 months

  37. Cmax of dostarlimab in combination with GSK5764227

    Time frame: Up to 27 months

  38. Cmax of dostarlimab in combination with remzistotug and belrestotug

    Time frame: Up to 27 months

  39. Cmax of dostarlimab in combination with belrestotug

    Time frame: Up to 27 months

  40. Cmax of dostarlimab in combination with belrestotug and remzistotug

    Time frame: Up to 27 months

  41. Cmax of dostarlimab in combination with belrestotug and nelistotug

    Time frame: Up to 27 months

  42. China cohort: Cmax of dostarlimab monotherapy

    Time frame: Up to 18 months

  43. Cmin of dostarlimab in Combination With remzistotug

    Time frame: Up to 27 months

  44. Cmin of dostarlimab in combination with GSK5764227

    Time frame: Up to 18 months

  45. Cmin of dostarlimab in combination with remzistotug and belrestotug

    Time frame: Up to 27 months

  46. Cmin of dostarlimab in combination with belrestotug

    Time frame: Up to 27 months

  47. Cmin of dostarlimab in combination with belrestotug and remzistotug

    Time frame: Up to 27 months

  48. Cmin of dostarlimab in combination with belrestotug and nelistotug

    Time frame: Up to 27 months

  49. China cohort: Cmin of dostarlimab monotherapy

    Time frame: Up to 18 months

  50. AUC(0-t) of dostarlimab in Combination With remzistotug

    Time frame: Up to 27 months

  51. AUC(0-t) of dostarlimab in combination with GSK5764227

    Time frame: Up to 18 months

  52. AUC(0-t) of dostarlimab in combination with remzistotug and belrestotug

    Time frame: Up to 27 months

  53. AUC(0-t) of dostarlimab in combination with belrestotug

    Time frame: Up to 27 months

  54. AUC(0-t) of dostarlimab in combination with belrestotug and remzistotug

    Time frame: Up to 27 months

  55. AUC(0-t) of dostarlimab in combination with belrestotug and nelistotug

    Time frame: Up to 27 months

  56. China cohort: AUC(0-t) of dostarlimab monotherapy

    Time frame: Up to 18 months

  57. AUC(0-infinity) of dostarlimab in Combination With remzistotug

    Time frame: Up to 27 months

  58. AUC(0-infinity) of dostarlimab in combination with GSK5764227

    Time frame: Up to 27 months

  59. AUC(0-infinity) of dostarlimab in combination with remzistotug and belrestotug

    Time frame: Up to 27 months

  60. AUC(0-infinity) of dostarlimab in combination with belrestotug

    Time frame: Up to 27 months

  61. AUC(0-infinity) of dostarlimab in combination with belrestotug and remzistotug

    Time frame: Up to 27 months

  62. AUC(0-infinity) of dostarlimab in combination with belrestotug and nelistotug

    Time frame: Up to 27 months

  63. China cohort: AUC(0-infinity) of dostarlimab monotherapy

    Time frame: Up to 18 months

  64. T1/2 of dostarlimab in Combination With remzistotug

    Time frame: Up to 27 months

  65. T1/2 of dostarlimab in combination with GSK5764227

    Time frame: Up to 18 months

  66. China cohort: T1/2 of dostarlimab monotherapy

    Time frame: Up to 18 months

  67. Cmax of belrestotug in combination with dostarlimab and belrestotug

    Time frame: Up to 27 months

  68. Cmax of belrestotug in combination with dostarlimab

    Time frame: Up to 27 months

  69. Cmax of belrestotug in combination with dostarlimab and remzistotug

    Time frame: Up to 27 months

  70. Cmax of belrestotug in combination with dostarlimab and nelistotug

    Time frame: Up to 27 months

  71. Cmin of belrestotug in combination with dostarlimab and belrestotug

    Time frame: Up to 27 months

  72. Cmin of belrestotug in combination with dostarlimab

    Time frame: Up to 27 months

  73. Cmin of belrestotug in combination with dostarlimab and remzistotug

    Time frame: Up to 27 months

  74. Cmin of belrestotug in combination with dostarlimab and nelistotug

    Time frame: Up to 27 months

  75. AUC (0-t) of belrestotug in combination with dostarlimab and belrestotug

    Time frame: Up to 27 months

  76. AUC (0-t) of belrestotug in combination with dostarlimab

    Time frame: Up to 27 months

  77. AUC (0-t) of belrestotug in combination with dostarlimab and remzistotug

    Time frame: Up to 27 months

  78. AUC (0-t) of belrestotug in combination with dostarlimab and nelistotug

    Time frame: Up to 27 months

  79. AUC (0-infinity) of belrestotug in combination with dostarlimab and belrestotug

    Time frame: Up to 27 months

  80. AUC (0- infinity) of belrestotug in combination with dostarlimab

    Time frame: Up to 27 months

  81. AUC (0- infinity) of belrestotug in combination with dostarlimab and remzistotug

    Time frame: Up to 27 months

  82. AUC (0- infinity) of belrestotug in combination with dostarlimab and nelistotug

    Time frame: Up to 27 months

  83. Cmax of nelistotug in combination with dostarlimab and belrestotug

    Time frame: Up to 27 months

  84. Cmin of nelistotug in combination with dostarlimab and belrestotug

    Time frame: Up to 27 months

  85. AUC (0-t) of nelistotug in combination with dostarlimab and belrestotug

    Time frame: Up to 27 months

  86. AUC (0-infinity) of nelistotug in combination with dostarlimab and belrestotug

    Time frame: Up to 27 months

  87. Cmax of GSK5764227 in combination with dostarlimab

    Time frame: Up to 18 months

  88. Cmin of GSK5764227 in combination with dostarlimab

    Time frame: Up to 18 months

  89. AUC (0-t) of GSK5764227 conjugated Ab in combination with dostarlimab

    Time frame: Up to 18 months

  90. AUC (0-t) of GSK5764227 small molecule toxin in combination with dostarlimab

    Time frame: Up to 18 months

  91. AUC (0-infinity) of GSK5764227 conjugated Ab in combination with dostarlimab

    Time frame: Up to 18 months

  92. AUC (0-infinity) of GSK5764227 small molecule toxin in combination with dostarlimab

    Time frame: Up to 18 months

07

Study locations

26 sites
  • GSK Investigational Site
    San Francisco, California 94158, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28204, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19111, United States
  • GSK Investigational Site
    Dallas, Texas 75230, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84112-5550, United States
  • GSK Investigational Site
    Nedlands, Western Australia 6009, Australia
  • GSK Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • GSK Investigational Site
    Chengdu, 610041, China
  • GSK Investigational Site
    Jinan, 250117, China
  • GSK Investigational Site
    Shanghai, 200126, China
  • GSK Investigational Site
    Wuhan, 430022, China
  • GSK Investigational Site
    Dijon, 21000, France
  • GSK Investigational Site
    Lille, 59000, France
  • GSK Investigational Site
    Chiba, 277-8577, Japan
  • GSK Investigational Site
    Tokyo, 104-0045, Japan
  • GSK Investigational Site
    Seoul, 03080, South Korea
  • GSK Investigational Site
    Seoul, 03722, South Korea
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28050, Spain
  • GSK Investigational Site
    Málaga, 29010, Spain
  • GSK Investigational Site
    Sutton, Surrey SM2 5PT, United Kingdom
  • GSK Investigational Site
    Manchester, M20 4BX, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Jun 2026, 51 months.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's 51 months is above that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2027 → Jun 2026, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2022
First posted
Mar 14, 2022
StartActual
Mar 22, 2022
Primary completionActual
Jun 30, 2026was Aug 2027
CompletionEst.
Aug 31, 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • GSK Investigational Site · Sutton, United Kingdom
Show 1 removed
  • GSK Investigational Site · Sutton, United Kingdom
Oct 19, 2026
Primary completion
Aug 31, 2027→Jun 30, 2026 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    1 site added, 1 site removed
    Show site
    • GSK Investigational Site · Sutton, United Kingdom
    Show 1 removed
    • GSK Investigational Site · Sutton, United Kingdom
    Primary completion Aug 31, 2027→Jun 30, 2026 (now actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05277051
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 14, 2022
Start date
Mar 22, 2022
Primary completion
Jun 30, 2026
Completion
Aug 31, 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Belrestotug · Nelistotug · Risvutatug rezetecan

Start the discussion